Skip to main content
SpringerLink
Log in

Factors Associated With Success of the Extreme Drug Resistance Assay in Primary Breast Cancer Specimens

  • Conference Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

The extreme drug resistance (EDR) assay has not been widely studied in the setting of non-metastatic breast cancer. We evaluated the feasibility of performing the assay in 144 primary breast tumor specimens from two institutions by determining the rate of successful tumor culture for assays, number of drugs evaluated per assay, and time from tumor biopsy to receipt of results. We also sought to determine factors that are associated with assay success. An exploratory analysis was performed to detect possible associations between estrogen receptor (ER), progesterone receptor (PR) and HER2/NEU over-expression and extreme drug resistance demonstrated by the assay for specific chemotherapeutic agents. Of 144 tumor specimens submitted, tumor was successfully cultured for assay in 101(70%) of cases. A median of five drugs was evaluated per assay (range 2–9). Results were obtained in a median of 8 days (range 2–29). Young age, high tumor grade, PR negativity, and higher tumor submission weight were predictive for a successful assay. EDR was observed in 7–15% of tumors to doxorubicin, cyclophosphamide, 5-fluorouracil (5FU) and mitoxantrone, but EDR to paclitaxel was observed in 35%. Extreme drug resistance to 5-FU was associated with negative ER and PR status. There was a trend toward association between EDR to paclitaxel and HER2/NEU over-expression. The EDR assay may be successfully performed in the majority of tumors, and assay results are available in a timely fashion such that adjuvant treatment drug selection could be guided by results. These results may be helpful for designing possible future trials that evaluate the assay's role in adjuvant chemotherapy selection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kern DH, Weisenthal LM: Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 82: 582–588, 1990

    Google Scholar 

  2. Cortazar P, Johnson BE: Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity for patients with cancer. J Clin Oncol 17: 1625–1631, 1999

    Google Scholar 

  3. Brown E, Markman J: Tumor chemosensitivity and chemoresistance assays. Cancer 77: 1020–1025, 1997

    Google Scholar 

  4. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB, Marchetti DL, Baker TR, Blumenson LE: Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol Oncol 70: 392–397, 1998

    Google Scholar 

  5. Azzopardi JG, Chepick OF, Hartmann WH, Jafarey NA, Llombart-Bosch A, Ozzello L, Rilke F, Sasano N, Sobin LH, Sommers SC, Stalsberg H, Sugar J, Williams AO: The World Health Organization histological typing of breast tumors. 2nd edn, Am J Clin Pathol 78: 806–816, 1982

    Google Scholar 

  6. Bloom HJG, Richardson WW: Histologic grading and prognosis in breast cancer: A study of 1709 cases of which 359 have been followed for 15 years. Br J Cancer 2: 353–377, 1957

    Google Scholar 

  7. Elston CW: Grading of invasive carcinoma of the breast. In: Page DL, Anderson TJ (eds) Diagnostic Histopathology of the Breast. Churchill Livingstone, New York, 1987, p303

    Google Scholar 

  8. Wilbur DC, Willis J, Mooney RA, Fallon RA, Moynes R, di Sant' Agnese PA: Estrogen and progesterone detection in archival formalin-fixed, paraffin-embedded tissue from breast carcinoma: a comparison of immunocytochemistry with dextran coated charcoal assay. Mod Pathol 5: 79–84, 1992

    Google Scholar 

  9. Bacus SS, Flowers JL, Press MF, Bacus JW, McCarty Jr KS: The evaluation of estrogen receptor in primary breast carcinoma by computer assisted image analysis. Am J Clin Pathol 90: 233–239, 1988

    Google Scholar 

  10. Boenisch T: Immunochemical staining methods handbook. In: Naish SJ, Farmilo AJ, Stead RH (eds) Staining Methods. Dako Corporation, Carpinteria California, 1989, pp 13–19

    Google Scholar 

  11. Slamon DJ, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eirmann W, Wolter J, Baselga J, Norton L: Addition of HerceptinTM (humanized anti-her2 antibody) to first line chemotherapy for her2 overexpressing metastatic breast cancer (her2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 17: 98a (abstr 377), 1998

  12. Mehta R, Bornstein R, Yu I, Parker R, Fruehauf J: Association between breast cancer survival and in vitro drug response in the EDR assay. Proc Am Soc Clin Oncol 19: 81a (abstr 310B), 2000

  13. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Conolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR: Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12: 888–894, 1994

    Google Scholar 

  14. Albain KS, Allred DC, Clark GM: Breast cancer outcome and predictors of outcome: are there age differentials? J Natl Cancer Inst (Mongr) 16: 35–42, 1994

    Google Scholar 

  15. Hug V, Thames H, Hortobagy G, Finders M: Chemosensitivities of human clonogenic breast tumor cells. Eur J Cancer Clin Oncol 22: 971–981, 1986

    Google Scholar 

  16. Silvestrini R, Daidone MG, Mastore M, Di Fronzo G, Coradini D, Boracchi P, Squicciarini P, Salvadore B, Veronesi U: Cell Kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 11: 1150–1155, 1993

    Google Scholar 

  17. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28: 9–20, 1993

    Google Scholar 

  18. Recht A, Come SE, Henderson IC, Gelman RS, Silver B, Hayes DF, Shulman LN, Harris JR: The sequencing of chemotherapy and radiation therapy after conservative surgery for patients with early-stage breast cancer. N Engl J Med 334: 1356–1361, 1996

    Google Scholar 

  19. Fruehauf JP, Kern DH: Previously treated breast cancer showed a 2-fold increased in 5FU resistance in vitro. Breast Ca Res Treat 23: 148 (abstr 70), 1992

    Google Scholar 

  20. Robert NJ, Miller JA, Fruehauf JP, Kern DH: Extreme drug resistance in untreated breast cancer. Breast Cancer Res Treat 23: 147 (abstr 68), 1992

    Google Scholar 

  21. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Marino S, Ingle JN, Cooper MR, Canellow G, Borden E, Fleming F, Holland JF, Graziano S, Carpenter J, Muss H, Norton L: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17: 101 (abstr 390a), 1998

  22. Belotti D, Vergami V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843–1849, 1996

    Google Scholar 

  23. Lau, DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14: 31–36, 1999

    Google Scholar 

  24. Henderson IC, Patek AJ: The relationship between prognostic and predictive factors in the management of breast cancer. Breast Cancer Res Treat 52: 261–288, 1998

    Google Scholar 

  25. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M: ErB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330: 1260–1266, 1994

    Google Scholar 

  26. Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: ErbB-2 and response to doxorubicin in patients with axillary lymphnode-positive, hormone receptor negative breast cancer. J Natl Cancer Inst 90: 1361–1370, 1998

    Google Scholar 

  27. Baselga J, Seidman AD, Rosen PP, Norton L: HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 11: 43–48, 1997

    Google Scholar 

  28. Ellis JM, Hayes DF, Lippman ME: Treatment of metastatic breast cancer. In: Harris JR, Lippmann ME, Morrow M, Osborne CK (eds) Diseases of the Breast. Lippincott Williams & Wilkins, Philadelphia, PA, 2000, pp 749–797

    Google Scholar 

  29. SEER Cancer Statistics Review: 1973–1998. http://seer.cancer.gov/publications/GSR1973-dy1988/

  30. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16: 2672–2685, 1988

    Google Scholar 

  31. Henderson CI: Adjuvant chemotherapy: taxanes. The ‘pro’ position. Program and abstracts of the NIH Consensus Development Conference: Adjuvant Therapy for Breast Cancer, November 1–3, 2000, Bethesda, Maryland

  32. Mamounas EP: NSABP B-28; initial results. Program and abstracts of the NIH Consensus Development Conference: Adjuvant Therapy for Breast Cancer, November 1–3, 2000, Bethesda, Maryland

  33. Piccart MJ: Adjuvant chemotherapy: taxanes. The ‘con’ position. Program and abstracts of the NIH Consensus Development Conference: Adjuvant Therapy for Breast Cancer, November 1–3, 2000, Bethesda, Maryland

Download references

Author information

Authors and Affiliations

  1. Division of Oncology, Department of Internal Medicine, USA

    Robert J. Ellis, Carol J. Fabian & Carlos Rubin Decelis

  2. Department of Radiation Oncology, USA

    Bruce F. Kimler

  3. Department of Pathology and Laboratory Medicine, USA

    Ossama Tawfik

  4. Kansas Cancer Institute, USA

    Matthew S. Mayo

  5. Department of Surgery, University of Kansas Medical Center, Kansas City, KS

    William R. Jewell & Carol Connor

  6. Department of Pathology, USA

    Carol Modrell

  7. Department of Surgery Lawrence Memorial Hospital, Lawrence, KS

    Mark Praeger & Marilee McGinness

  8. Department of Internal Medicine, Division of Hematology-Oncology, University of California, Oncotech, Inc., Irvine, CA, USA

    Rita Mehta & John P. Fruehauf

Authors
  1. Robert J. Ellis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol J. Fabian
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bruce F. Kimler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ossama Tawfik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Matthew S. Mayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlos Rubin Decelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. William R. Jewell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carol Connor
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Carol Modrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Mark Praeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marilee McGinness
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Rita Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. John P. Fruehauf
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ellis, R.J., Fabian, C.J., Kimler, B.F. et al. Factors Associated With Success of the Extreme Drug Resistance Assay in Primary Breast Cancer Specimens. Breast Cancer Res Treat 71, 95–102 (2002). https://doi.org/10.1023/A:1013843912560

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1013843912560

Search

Navigation